Do gabapentin or pregabalin directly modulate the µ receptor?
Background Pregabalin and gabapentin improve neuropathic pain symptoms but there are emerging concerns regarding their misuse. This is more pronounced among patients with substance use disorder, particularly involving opioids. Co-ingestion of gabapentinoids with opioids is increasingly identified in...
Auteurs principaux: | Preeti Manandhar, Bridin Patricia Murnion, Natasha L. Grimsey, Mark Connor, Marina Santiago |
---|---|
Format: | Article |
Langue: | English |
Publié: |
PeerJ Inc.
2021-04-01
|
Collection: | PeerJ |
Sujets: | |
Accès en ligne: | https://peerj.com/articles/11175.pdf |
Documents similaires
-
Gabapentin and pregabalin exposures reported to United States poison centers, 2012–2022
par: Emily J.R. Carter, et autres
Publié: (2024-11-01) -
A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder
par: Qin Xiang Ng, et autres
Publié: (2021-08-01) -
Efficacy and safety of pregabalin and gabapentin in spinal stenosis: a systematic review and meta-analysis
par: Telmo Martínez, et autres
Publié: (2023-11-01) -
Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids
par: Payal H. Desai, PharmD, BCCCP, et autres
Publié: (2021-07-01) -
Gabapentin and Pregabalin in chronic neuropathic pain: cost efficacy evaluation
par: Paolo Marchettini, et autres
Publié: (2005-05-01)